Semaglutide for Diabetes — Which Medicines Are Licensed for What

The decision in front of you: diabetes treatment, weight management, or both?

A question our prescribers hear most weeks goes something like this: "I have type 2 diabetes and my doctor mentioned semaglutide, but I've also seen Wegovy advertised for weight loss. Are they the same thing?" They contain the same active ingredient. The difference lies in the dose, the licensed indication, and where the prescription comes from.

Ozempic (the injectable used for diabetes) runs at up to 2mg weekly. Wegovy runs at 2.4mg weekly, and is specifically licensed for weight management rather than blood-sugar control. If your GP or diabetes team wants to treat your type 2 diabetes with semaglutide, they will almost certainly prescribe Ozempic or Rybelsus through your NHS pathway. Wegovy sits in a different lane. The relationship between Wegovy and type 2 diabetes is real (many people with the condition qualify for it as a weight-loss medicine) but the prescribing rationale is weight management, not glycaemic control as a primary goal.

So the decision is: what does your clinical picture actually need? If your diabetes is the central concern, your diabetes team leads. If excess weight is causing or worsening your diabetes and other conditions, weight-management treatment alongside diabetes care may be relevant. These are not mutually exclusive; they require coordinated clinical thinking.

What semaglutide can and cannot do for people with diabetes

For type 2 diabetes, semaglutide has a well-established evidence base. It lowers HbA1c, reduces appetite, and carries a lower hypoglycaemia risk than some older agents. The cardiovascular data are significant too, the SELECT trial showed a reduction in major cardiovascular events in people with obesity and established cardiovascular disease, which overlaps heavily with the type 2 diabetes population.

Wegovy holds its own cardiovascular indication in the UK, separate from the weight-management licence. The intersection of Wegovy and diabetes is therefore meaningful: if you have type 2 diabetes plus obesity plus cardiovascular risk, a specialist may see Wegovy as relevant on more than one clinical ground.

What semaglutide cannot do is treat type 1 diabetes. It is not licensed for that use, and the evidence around semaglutide in type 1 diabetes remains limited and specialist-led. If you have type 1 and are curious, the right conversation is with your endocrinologist or diabetes team, not an online pharmacy. The risks around hypoglycaemia and DKA in this context require close clinical oversight that a private weight-loss service is not designed to provide.

It is also worth being clear about oral options: Rybelsus (3mg, 7mg, 14mg tablets) is licensed for type 2 diabetes. It is not the same product as Wegovy tablets. The recently approved oral Wegovy (25mg maintenance dose) is a different formulation licensed for weight management. Mixing these up is an easy mistake, and if you want to understand whether semaglutide is appropriate for type 2 diabetes specifically, the NHS medicines pages for semaglutide set out the distinction clearly.

NICE guidance: who qualifies for semaglutide on the NHS, and what that means for you

For weight management, NICE recommends Wegovy (TA875) within specialist weight management services for adults meeting specific BMI thresholds, generally BMI 35 or above, with at least one weight-related comorbidity, for a maximum of two years. Type 2 diabetes counts as a qualifying comorbidity. The NICE guidance on semaglutide and diabetes has practical implications for NHS access, though waiting lists in specialist services are often long.

For type 2 diabetes treatment specifically, NICE recommends semaglutide (Ozempic) as an option within the diabetes medicines pathway, your GP or diabetologist will know whether it fits your HbA1c trajectory, other medicines, and cardiovascular profile. The NICE appraisal of semaglutide for weight management (TA875) is publicly available if you want to read the exact criteria.

Private routes exist for weight management (nume is one of them) but we prescribe Wegovy for weight loss, not as a diabetes treatment. People with well-controlled or managed type 2 diabetes can be eligible, subject to a full clinical assessment by our prescribing team. People whose diabetes requires active specialist input should have that team involved in any decision to add or switch a medicine.

Pregnancy, breastfeeding, and planning a family

Semaglutide (in any form, for any indication) is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. This applies equally to Ozempic, Rybelsus, and Wegovy. For people with type 2 diabetes who need blood-sugar management during pregnancy, insulin remains the established safe option, and a specialist obstetric diabetes team should lead care. Anyone on semaglutide who becomes pregnant or is planning to should speak to their GP or diabetes team promptly. The guidance on Wegovy and pregnancy covers the washout period and contraception recommendations in more detail. Under-18s are not licensed for semaglutide for either indication.